曲安奈德玻璃体注射治疗黄斑水肿的安全性长期随访分析

目的:观察2 mg、4 mg曲安奈德玻璃体注射治疗黄斑水肿的长期安全性。方法:将54例黄斑水肿患者分别采用2 mg和4mg不同剂量的曲安奈德玻璃体内注射,随访2年,观察眼压、晶状体、眼内炎症、视网膜、玻璃体等并发症。结果:两种剂量曲安奈德玻璃体内注射均可产生高眼压、白内障、非感染性眼内炎症;4 mg组白内障发生率明显高于2 mg组,其余并发症未见明显差异;两组患者均未出现严重、不可逆并发症。结论:2 mg和4 mg曲安奈德玻璃体注射治疗黄斑水肿均较安全,4 mg剂量更容易发生白内障,两种计量均需长期随访。

Long-termFollow-up of Safety of Intravitreous Injection with TriamcinoloneAcetonide on Macular Edema

Objective:To study the long-term safety of intravitreous injection with 2 mg and 4mg triamcinolone acetonide(TA) formacular edema.Methods:54 cases of patients with macular edema were treated by intravitreous injection of 2 mg or 4 mg TA. The IOP,lens, inflammation, retina and vitreous were followed up for 2 years for all cases.Results:Two doses of intravitreous injection withtriamcinolone acetonide could produce high intraocular pressure, cataract and non-infectious uveitis. The incidence of cataract of 4mggroup was significantly higher than that in 2 mg group, but there was no significant difference between two groups in other complications.The serious, irreversible complications were not found in any patient.Conclusion:2 mg and 4 mg intravitreous injection of TA have thesame long-termclinical safety for macular edema, and need follow-up for a long time. The dose of 4mg is more likely to induce cataract.